Felzartamab is under clinical development by MorphoSys and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Felzartamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Felzartamab overview

Felzartamab is under development for the treatment of late antibody-mediated renal allograft rejection, IgA nephropathy (IgAN), membranous nephropathy(anti-PLA2R antibody-positive membranous nephropathy), refractory/relapsed multiple myeloma and lupus nephritis (systemic lupus erythematosus). The drug candidate is administered as an intravenous infusion. It is a fully human monoclonal antibody (mAb) directed against CD38, which is one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells.

It was also under development for the treatment of non-small lung cancer, systemic lupus erythematosus.

MorphoSys overview

MorphoSys is a biopharmaceutical company that develops monoclonal antibodies for therapeutic and research applications, with a focus on the treatment of cancer and autoimmune diseases. The company’s clinical programs include Pelabresib, a small molecule BET inhibitor for anti-tumor activity and Tulmimetostat, a dual inhibitor of EZH2 and EZH1 for anti-tumor activity. It provides clinical trials for cancer and inflammatory disorders. MorphoSys also conducts research and development activities with pharmaceutical and biotechnology companies. It operates through subsidiaries in the US and Germany. MorphoSys is headquartered in Planegg, Bayern, Germany.

For a complete picture of Felzartamab’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.